When Is Disease-Specific Therapy Started for Cardiac Amyloidosis? How Specialists Decide

The echocardiogram report had a phrase on it that Richard’s cardiologist read aloud twice: “thickened ventricular walls, consider infiltrative process.” He had come in for breathlessness on the stairs. He left with a bone scan appointment, a urine test and a word he had never heard before. Amyloidosis. His first question was not what it meant. It was when something would be done about it.

That instinct is understandable, and the answer is more interesting than “as soon as possible.” The timing of cardiac amyloidosis treatment options depends almost entirely on which protein is building up in the heart muscle, and specialists will not start disease-specific therapy until they know. One form behaves like a fast-moving blood cancer. The other unfolds over years. Treating the wrong one would be useless at best and harmful at worst.

This explainer walks through how that decision is made, what the treatments actually do, and what the first months usually look like.

What cardiac amyloidosis is, and why the type decides everything

Amyloidosis is a group of conditions in which a normally soluble protein misfolds, clumps into stiff fibers called amyloid fibrils, and deposits in tissues. When those fibrils lodge in heart muscle, the walls thicken and stiffen, the chambers struggle to fill between beats, and the electrical system can misfire. That is cardiac amyloidosis.

Two proteins account for almost all cases. The first is a fragment of antibody called a light chain, produced in excess by abnormal plasma cells in the bone marrow; this is AL amyloidosis, and it is closely related to blood cancers such as myeloma. The second is transthyretin, a transport protein made in the liver that carries thyroid hormone and vitamin A around the body; this is ATTR amyloidosis. ATTR comes in two flavors: a hereditary form caused by a gene variant, and a wild-type form that appears with aging and no inherited mutation at all.

Why does this matter for timing? Because the two diseases move at different speeds and respond to opposite strategies. Light chains are directly toxic to heart cells, and untreated AL amyloidosis with cardiac involvement can progress over months. Transthyretin deposits accumulate more slowly, often over years, before symptoms appear. The American Heart Association’s scientific statement on cardiac amyloidosis is blunt that identifying the type is the single most consequential step, since every treatment that follows depends on it.

Think of it this way. Both conditions leave the same debris in the heart. One is a burst pipe that must be shut off today; the other is a slow leak that still needs fixing, but with a different tool. Nobody sensible picks up the tool before finding the leak.

How disease-specific therapy actually works

Disease-specific therapy means treatment aimed at the amyloid-producing process itself, rather than at the symptoms it causes. Diuretics that ease fluid buildup are supportive therapy. Medicines that stop light chains or transthyretin from forming new fibrils are disease-specific. Both matter, but only the second changes the trajectory of the disease.

For AL amyloidosis, the target is the abnormal plasma cell clone in the bone marrow. Chemotherapy-based regimens, often including a proteasome inhibitor (a drug class that disrupts protein recycling inside cancer cells) and a monoclonal antibody directed at plasma cells, aim to shut down light-chain production. Fewer circulating light chains means less new amyloid and less direct toxicity to heart muscle. In selected, fitter patients, high-dose chemotherapy followed by a stem cell transplant using the person’s own cells is another route to the same goal.

For ATTR, the liver keeps making transthyretin, so the strategies are to keep the protein in its stable four-part shape or to reduce how much of it is made. Stabilizers are oral medicines that bind to transthyretin and discourage it from splitting into the misfolding fragments that form fibrils. Gene silencers are injected medicines (small interfering RNA or antisense oligonucleotides, both of which block the genetic instructions for the protein) that lower transthyretin production in the liver by a large margin.

Neither approach dissolves amyloid already in the heart. Current therapies slow or halt new deposition; the body may clear some existing material over time, but that is not something clinicians can promise. Treatments designed to actively remove deposits are in clinical trials and remain investigational. This is why timing matters: the less amyloid present when therapy starts, the more heart function there is to protect.

Cardiac amyloidosis treatment options compared: a side-by-side table

Patients often arrive at the clinic having read about one treatment and assume it applies to them. The table below shows why the first question is always “which type?”

Feature	AL (light chain) cardiac amyloidosis	ATTR cardiomyopathy (hereditary or wild-type)
Source of the protein	Abnormal plasma cells in bone marrow	Normal liver production of transthyretin
Usual speed of progression	Months if untreated	Years, slower in wild-type
Disease-specific therapy	Chemotherapy-based regimens; stem cell transplant in selected patients	Transthyretin stabilizers (oral) or gene silencers (injected)
Typical timing of start	Urgent, usually within days to a few weeks of confirmed diagnosis	Soon after confirmed diagnosis in symptomatic heart disease; monitoring in some early or very advanced cases
Specialist leading treatment	Hematologist with cardiology input	Cardiologist, often with neurology if nerves are involved
How response is tracked	Blood free light chain levels, heart biomarkers, echocardiography	Heart biomarkers, functional tests, echocardiography, symptoms
Supportive care	Diuretics, rhythm management, blood pressure support	Diuretics, rhythm management, pacemaker if needed

A few things stand out. The hematologist, a specialist in blood disorders, is the lead in AL even though the heart is the organ in trouble, because the problem originates in the marrow. ATTR care is led from cardiology, with genetic counseling added when a hereditary variant is found. Supportive measures overlap heavily, and the AHA statement notes that careful fluid management remains the backbone of day-to-day symptom control in both forms.

What the table cannot show is the individual judgment that sits around each cell: kidney function, frailty, other heart disease, and what the person wants from treatment.

Why specialists confirm the type before starting anything

It would be faster to start treatment on suspicion. Specialists do not, and the reasons are not bureaucratic.

Typing begins with blood and urine tests for abnormal light chains. If those are negative, a nuclear medicine bone scan using a tracer that binds to transthyretin deposits can confirm ATTR without a biopsy in many people; the AHA statement describes this non-invasive pathway as a major shift in how the disease is diagnosed. If light chain tests are abnormal, however, the bone scan alone cannot settle the question, because some people have both a harmless plasma cell abnormality and ATTR deposits. In that situation a tissue biopsy, often from abdominal fat, bone marrow or the heart itself, is examined with mass spectrometry or immunohistochemistry to identify the exact protein.

Getting this wrong has real consequences. Giving chemotherapy to someone with ATTR exposes them to toxic drugs that cannot help. Giving a transthyretin stabilizer to someone with AL wastes the narrow window in which light-chain suppression can protect the heart. Genetic testing is added in every ATTR case, since a hereditary variant changes the picture for relatives and may open eligibility for additional treatments.

How long does this take? Typing can often be completed within a couple of weeks when a center is set up for it, though biopsy and specialist review add time. The Mayo Clinic’s patient information describes amyloidosis as frequently diagnosed late because early symptoms mimic common conditions, and that delay, rather than the typing process itself, is usually the larger problem.

Richard, from the opening, had a negative light chain screen and a strongly positive bone scan. His team moved to treatment planning without needing a heart biopsy. Someone with an abnormal light chain result would have followed a different and more urgent road.

Who usually starts therapy soon, and who is usually asked to wait

Once the type is known, the decision becomes a weighing exercise rather than a single rule.

People usually started promptly include anyone with confirmed AL amyloidosis and heart involvement, since delay allows ongoing toxicity. Also in this group are people with symptomatic ATTR cardiomyopathy, meaning heart failure symptoms such as breathlessness or swelling together with imaging and biomarker evidence of cardiac deposits. The randomized trial of a transthyretin stabilizer published in 2018 enrolled people in this category, and most guideline recommendations for ATTR therapy are built on that population.

People sometimes asked to wait, or to be monitored, fall into a few categories:

• Carriers of a hereditary transthyretin variant who have no detectable amyloid in the heart. Monitoring with periodic imaging and biomarkers is usual; treatment is generally considered once deposits or symptoms appear.
• People in whom typing is incomplete or results conflict. Starting the wrong therapy is worse than a short delay.
• People with very advanced heart failure, where evidence for benefit is thinner and the burden of treatment may outweigh it. Here the conversation often widens to include supportive care and, in some cases, transplant assessment.
• People with an unrelated acute illness or unstable kidney function, where therapy is deferred until they are stable enough.

“Wait” rarely means “do nothing.” Supportive treatment of fluid and rhythm problems begins immediately regardless of type. What is being postponed is the disease-specific medicine, and only until the information needed to choose it safely is in hand.

Every one of these judgments belongs to the treating team, who can see the full picture of stage, organ function and the person’s own priorities.

AL amyloidosis heart treatment: why speed matters more here

If one message survives from this article, it should be this: cardiac AL amyloidosis is a hematologic emergency dressed up as heart failure.

Light chains do two kinds of damage. They form fibrils that stiffen the heart, and they are directly toxic to heart muscle cells through oxidative stress, a chemical process that injures cell structures. The second mechanism explains why heart function can deteriorate quickly even before deposits look dramatic on imaging, and why lowering light chains can produce measurable improvement in heart biomarkers within weeks in people who respond, as described in the AHA statement.

Treatment is staged according to how much heart damage is already present, using blood markers such as troponin (a protein released by injured heart muscle) and natriuretic peptides (hormones the heart releases when stretched). Higher stages carry higher early risk, and the regimen and its intensity are adjusted accordingly. Hematologists typically combine several drug classes: a proteasome inhibitor, a steroid, an alkylating agent and a monoclonal antibody against a surface marker on plasma cells. Which combination, and for how long, is a decision made cycle by cycle based on how light chain levels respond.

Stem cell transplantation using the person’s own harvested cells can produce deep and durable responses, but it requires reasonable heart and kidney function to tolerate the high-dose chemotherapy that precedes it. Many people with significant cardiac involvement are not candidates at diagnosis, though some become eligible after initial treatment reduces their light chain burden.

The heart team’s job during AL treatment is to keep the person stable through it: managing fluid without dropping blood pressure, watching for rhythm disturbances, and recognizing when a hospital stay is safer than outpatient care. This is genuinely two specialties working on one patient at the same time.

ATTR cardiomyopathy treatment: what stabilizers and silencers do

Transthyretin normally circulates as a tetramer, a cluster of four identical units. Trouble starts when the tetramer dissociates into single units that misfold and stick together. Both approved classes of ATTR therapy intervene at this step, just from different directions.

Stabilizers are taken by mouth. They slot into a binding pocket on the tetramer and hold the four units together, so fewer single units are available to misfold. The first stabilizer approved for cardiomyopathy was studied in a 30-month randomized trial of people with symptomatic ATTR heart disease; the published results in the New England Journal of Medicine reported lower rates of death and cardiovascular hospitalization in the treated group compared with placebo, with benefit emerging gradually over the trial period rather than immediately. A second-generation stabilizer has since been developed and studied along similar lines.

Gene silencers take a different route. Small interfering RNA and antisense oligonucleotide medicines are given by injection, either into a vein or under the skin, and travel to the liver, where they interrupt the messenger RNA that carries the instructions for making transthyretin. Production falls sharply, so the supply of misfolding-prone protein shrinks. These agents were first approved for the nerve form of hereditary ATTR and have since been studied in cardiomyopathy.

Which class a given person receives depends on whether the variant is hereditary, whether nerves are involved, kidney and liver function, how frequently they can attend for injections, and local regulatory approvals. These are not interchangeable, and neither is “stronger” in a way that applies to everyone. The prescribing cardiologist weighs the evidence base for each in the specific clinical situation.

One practical note: because transthyretin carries vitamin A, people on silencers are usually monitored for deficiency. That is a mechanism question, not a reason to self-supplement.

What is the new drug for cardiac amyloidosis?

This is among the most-searched questions on the topic, and the honest answer is that there is no single “new drug.” There are several, approved at different times in different countries, and the one being discussed in any given news story depends on where and when you are reading.

The landscape has moved in roughly three waves. First came oral transthyretin stabilizers, extending into cardiomyopathy a strategy originally studied for nerve disease. Then came gene silencers, initially approved for hereditary ATTR with neuropathy and later evaluated in cardiomyopathy. Most recently, antibodies designed to bind amyloid deposits already in tissue and recruit the immune system to clear them have entered late-stage trials for both AL and ATTR. These depleting antibodies are the ones most often described as “new,” and as of the trials published so far they remain investigational for cardiac disease.

What should a patient take from this? Three things, in order of importance.

The type still comes first. No new agent changes the fact that AL and ATTR require different treatments, and a medicine making headlines for one form is irrelevant to the other.

Approval is not the same as suitability. Regulators approve a medicine for a defined population based on trial entry criteria. A person outside those criteria, because of kidney function, disease stage or other conditions, may reasonably be offered something else.

Trials are a legitimate option, not a last resort. Many amyloidosis centers enroll patients in studies of newer agents, and the AHA statement encourages trial participation given how much remains unknown. Asking the care team whether a trial is appropriate is a reasonable question at any stage, and the answer sits with them.

What the first weeks and months of treatment usually look like

Starting disease-specific therapy rarely feels dramatic. The medicines work on protein production or stability, and the heart responds slowly to a reduced supply of amyloid.

In AL amyloidosis, the early period is the busiest. Chemotherapy is given in cycles, with blood tests before each one to check light chain levels, blood counts and kidney function. Hematologists look for a fall in the abnormal light chain, usually assessed after the first one or two cycles, to judge whether the regimen is working; an inadequate response prompts a change. Side effects such as fatigue, nerve tingling and infection risk are monitored closely. Cardiology visits run in parallel to adjust diuretics as fluid shifts, and the AHA statement notes that heart biomarkers can begin to improve within weeks when light chains fall, though symptom improvement typically lags behind.

In ATTR, the rhythm is gentler. An oral stabilizer is taken daily; a silencer is given by injection on a schedule set by the specific medicine, ranging from every few weeks to every few months. Baseline measurements are taken: a six-minute walk test, quality-of-life questionnaires, natriuretic peptide levels and an echocardiogram. These are repeated at intervals, often every six to twelve months, to track trajectory. In the pivotal stabilizer trial, the separation between treated and placebo groups became apparent after roughly 18 months, which is a useful anchor for expectations. People should not expect to feel different in the first month, and feeling the same is not evidence of failure.

Throughout both pathways, supportive care continues. Weight is checked daily at home to catch fluid gain early. Blood pressure is watched because amyloid affects the nerves that regulate it. A pacemaker may be fitted if the heart’s conduction system is affected. None of this is secondary; it is what keeps people well enough for the disease-specific therapy to do its slower work.

Which medications are avoided in cardiac amyloidosis, and why

People with a new diagnosis are often surprised to learn that standard heart failure medicines can be poorly tolerated or actively harmful in cardiac amyloidosis. The reasons come down to physiology.

An amyloid-infiltrated heart is stiff and cannot increase the amount of blood it pumps per beat. It maintains output largely by heart rate. Medicines that slow the heart therefore remove the one compensation the heart has left. For this reason, the AHA statement and other guideline sources describe non-dihydropyridine calcium channel blockers (a class that slows heart rate and relaxes vessels) as generally contraindicated, partly because they can also bind to amyloid fibrils and accumulate. Beta blockers, a mainstay in other heart failure, are often poorly tolerated and are typically used cautiously or withdrawn if blood pressure or symptoms worsen.

Blood pressure drugs such as ACE inhibitors and angiotensin receptor blockers can cause marked drops in pressure, because amyloid frequently damages the autonomic nerves that normally keep pressure steady on standing. Digoxin, which strengthens contraction, also binds to amyloid fibrils and has a narrow safety margin; it is used only with caution and monitoring.

The practical lesson is not a list to memorize. It is that anyone with cardiac amyloidosis should make sure every prescriber, including those treating unrelated conditions, knows the diagnosis before writing a prescription. Pharmacists can help flag interactions. If a person is already taking one of these medicines when diagnosed, the right step is to raise it with the cardiologist rather than stopping on their own, since abrupt withdrawal of some heart drugs carries its own risks.

Nothing in this section is advice to start, stop or change a medicine. It explains why the specialist managing amyloidosis may make choices that look unusual compared with standard heart failure care.

Cardiac amyloidosis life expectancy: what the evidence actually shows

“How long can you live with cardiac amyloidosis?” is the question people type late at night, and it deserves a straight answer rather than reassurance.

The honest response is that outlook varies enormously by type, by stage at diagnosis, and by whether effective treatment is started. The AHA scientific statement summarizes historical data showing that untreated AL amyloidosis with significant heart involvement carried a median survival measured in months, while wild-type ATTR cardiomyopathy without disease-specific therapy was associated with a median survival of roughly three to four years from diagnosis, with hereditary forms varying by the specific variant. Those figures come from the era before current therapies and from populations often diagnosed late.

Treatment changes the picture, and this is where caution about numbers matters. The 2018 stabilizer trial reported fewer deaths over 30 months in the treated group; modern AL regimens produce deep light-chain responses in a substantial proportion of patients, and people who achieve those responses tend to do better. What these studies cannot tell any individual is their own trajectory. Staging systems, which combine troponin and natriuretic peptide levels and, for AL, the light-chain burden, are the tools clinicians use to estimate risk, and even they describe groups rather than persons.

Several factors are consistently associated with better outcomes across studies: earlier diagnosis, lower biomarker stage at the start of treatment, a good response to therapy, and preserved kidney function. This is the evidence-based argument for not delaying evaluation when amyloidosis is suspected.

A person asking this question deserves a conversation with their own team, who can look at their stage, their response so far and their other health conditions. Population figures are a starting point for that conversation, never a verdict.

What people often get wrong about cardiac amyloidosis treatment options

A handful of misconceptions come up again and again in clinic, and each one can lead to a worse decision.

“It is a rare disease, so it is probably not that.” Wild-type ATTR cardiomyopathy was long considered rare, but the AHA statement describes evidence that it is substantially underdiagnosed, particularly in older adults with heart failure and preserved pumping function. Rarity is partly an artifact of not looking.

“The treatment will reverse the damage.” Current therapies are designed to slow or stop new amyloid deposition. Some heart measures can improve, especially in AL when light chains fall, but structural reversal is not something clinicians can promise, and antibodies aimed at clearing deposits remain under study.

“Standard heart failure medicines will help.” As the earlier section explained, several of them can make things worse. This is one of the few conditions where “less heart medicine” can be the evidence-based choice.

“Hereditary means my children will definitely get it.” A variant is passed on with a 50 percent chance for each child of an affected parent, as the NHS explains, but carrying the variant does not guarantee disease, and age of onset varies widely. Genetic counseling exists precisely to work through this.

“If I feel the same after three months, the treatment is not working.” Benefit from ATTR therapy accrues over many months, and the trial evidence shows separation from placebo well after the first year. Early stability is the expected result, not a failure.

“A diagnosis of AL means I have cancer.” AL amyloidosis is caused by a plasma cell disorder and treated with cancer medicines, but only a minority of people meet criteria for myeloma. The distinction matters for both prognosis and treatment intensity, and the hematologist can explain where an individual falls.

Questions to ask your care team

Appointments after an amyloidosis diagnosis are dense with information. Bringing written questions helps, and so does bringing someone to take notes. These are the questions that specialists most often wish patients had asked earlier.

• Which type of amyloidosis do I have, and how certain is that result? Was a tissue sample typed, or was the diagnosis made from blood tests and a scan alone?
• If it is ATTR, is it hereditary or wild-type, and has genetic testing been done? Who in my family might benefit from counseling?
• What stage is my heart involvement, and what do my troponin and natriuretic peptide levels suggest?
• Which disease-specific therapies am I a candidate for, and what makes one more suitable than another in my case?
• How will we know whether the treatment is working, and how often will those measurements be repeated?
• Which of my current medicines should be reviewed in light of this diagnosis?
• Are there clinical trials for which I might be eligible, and would participating change my standard care?
• Which symptoms should prompt me to call, and whom do I call, including out of hours?
• Who coordinates my care between cardiology and hematology or neurology?
• What is the realistic goal of treatment for me: stabilizing, improving, or preparing for other options such as transplant assessment?

A good team welcomes these questions. The answers will be specific to one person’s results, which is exactly why no article can supply them. If the answers are unclear, it is reasonable to ask for them to be written down or for a follow-up call. Treatment decisions in amyloidosis are rarely made in a single visit, and understanding the reasoning behind them is part of the treatment.

When to call your doctor

Cardiac amyloidosis is a condition in which small changes can signal something that needs attention quickly, because the stiff heart has little reserve. The following signs should prompt a same-day call to the care team, or emergency services if severe.

• Rapid weight gain, typically more than two to three pounds in a day or five pounds in a week, which usually means fluid is accumulating faster than the kidneys and diuretics can remove it.
• New or worsening breathlessness, especially breathlessness at rest or waking at night gasping for air.
• Fainting or near-fainting, particularly on standing. In amyloidosis this can reflect a dangerous rhythm disturbance or a fall in blood pressure that needs assessment.
• A sustained racing, pounding or irregular heartbeat, or a heart rate that feels unusually slow with dizziness.
• Chest pain or pressure, which should always be treated as an emergency.
• Fever during AL chemotherapy, since treatment lowers resistance to infection and a fever can be the only early sign.
• Markedly reduced urine output or a sudden rise in ankle and abdominal swelling, which may indicate worsening kidney or heart function.
• New confusion, severe weakness or an inability to keep medicines down.

Call emergency services immediately for collapse, chest pain lasting more than a few minutes, or severe breathlessness that does not ease with rest.

Between emergencies, keeping a daily log of weight, blood pressure and symptoms gives the team the information they need to adjust treatment before a crisis. The Johns Hopkins patient resource on cardiac amyloidosis emphasizes that close follow-up is itself part of the therapy. No sign on this list is too minor to report, and the people best placed to judge its significance are the ones who know your case.

Frequently asked questions

How long can you live with cardiac amyloidosis?

It depends heavily on the type, the stage at diagnosis and the response to treatment. Historical data summarized by the American Heart Association show untreated AL cardiac amyloidosis had a median survival of months, while untreated wild-type ATTR cardiomyopathy averaged roughly three to four years. Modern therapies have improved on those figures, and staging with blood biomarkers helps the treating team estimate an individual’s outlook.

What is the new drug for cardiac amyloidosis?

There is no single new drug; several classes have arrived in waves. Oral transthyretin stabilizers came first for ATTR cardiomyopathy, followed by injected gene silencers that reduce transthyretin production in the liver. Antibodies designed to clear existing amyloid deposits are the newest category and remain in clinical trials. Which, if any, suits a given person depends on type, stage and other health conditions.

How bad is cardiac amyloidosis?

It is a serious condition because amyloid stiffens the heart and leaves it little reserve, but severity ranges widely. AL amyloidosis with heart involvement can progress over months without treatment, while ATTR typically unfolds over years. Earlier diagnosis and lower biomarker stage at treatment start are consistently associated with better outcomes, which is why prompt evaluation matters when the diagnosis is suspected.

What medications should be avoided in patients with cardiac amyloidosis?

Guideline sources describe non-dihydropyridine calcium channel blockers as generally contraindicated, since they slow the heart and can bind to amyloid fibrils. Beta blockers, ACE inhibitors, angiotensin receptor blockers and digoxin are used cautiously because they may lower blood pressure or heart rate the stiff heart depends on. Any change to existing medicines should be made with the prescribing clinician, never independently.

What are the main cardiac amyloidosis life expectancy factors doctors look at?

Clinicians use staging systems built on blood levels of troponin and natriuretic peptides, which reflect heart injury and strain, plus the light-chain burden in AL disease. Kidney function, the specific transthyretin variant in hereditary cases, and how well the disease responds to therapy also shape the estimate. These tools describe groups, so the treating team interprets them for the individual.

How is ATTR cardiomyopathy treatment different from AL treatment?

ATTR treatment targets a normal liver protein, transthyretin, either by stabilizing it with an oral medicine or by reducing its production with an injected gene silencer. AL treatment targets abnormal plasma cells in the bone marrow using chemotherapy-based regimens and, in selected patients, stem cell transplant. Cardiology leads ATTR care; hematology leads AL care with cardiology support.

Why does AL amyloidosis heart treatment have to start so quickly?

Light chains are directly toxic to heart muscle cells in addition to forming deposits, so every week of continued production adds injury. The American Heart Association statement notes that heart biomarkers can begin to improve within weeks once light chains fall in responding patients. That window is why hematologists treat cardiac AL as an urgent condition once the type is confirmed.

Can you be diagnosed with ATTR without a heart biopsy?

Yes, in many cases. A nuclear bone scan using a tracer that binds to transthyretin deposits can confirm ATTR when blood and urine tests show no abnormal light chains. If light chain tests are abnormal, a tissue sample is still needed to determine the protein type, because both conditions can coexist. Genetic testing is then added to distinguish hereditary from wild-type disease.

How long before cardiac amyloidosis treatment options show results?

Timelines differ by type. In AL amyloidosis, light-chain levels are usually reassessed after the first one or two chemotherapy cycles to judge response. In ATTR, the pivotal stabilizer trial showed treated and placebo groups diverging after roughly 18 months, so early stability rather than improvement is the expected outcome. Response is tracked with biomarkers, walk tests and imaging at set intervals.

Should family members be tested if I have hereditary ATTR?

Genetic counseling is usually offered to first-degree relatives, since each child of an affected parent has a 50 percent chance of inheriting the variant, according to the NHS. Carrying the variant does not guarantee disease, and age of onset varies. Relatives who test positive are typically monitored rather than treated until amyloid deposits or symptoms appear.

References

• Amyloidosis (NHS)
• Amyloidosis (MedlinePlus)

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.